Navigation Links
FDA clears test developed in partnership with VCU researcher
Date:5/22/2012

RICHMOND, Va. (May 22, 2012) The Food and Drug Administration has approved a new test to help physicians diagnose a group of rare cell disorders. The test, or assay, was developed by an expert at Virginia Commonwealth University in the field of mast cells.

Lawrence Schwartz, M.D., Ph.D., chair of the Division of Rheumatology, Allergy and Immunology and the Charles and Evelyn Thomas Professor of Medicine at VCU, has spent more than 30 years researching mast cells. These cells are vital to the inflammatory process within the body and may play protective roles in wound healing and fighting infections.

"When a mast cell is triggered, it releases several strong chemicals into the body, including histamine and tryptase. Histamine causes itching, swelling, wheezing and sneezing and other signs and symptoms of allergic reactions," said Schwartz.

Mastocytosis, a group of rare chronic disorders found in both children and adults, is caused by the presence of too many of these mast cells in the body. If there are too many mast cells, the increased burden of chemicals released from these cells can cause several symptoms that range in intensity from mild to severe.

Because mast cells play a role in allergic reactions, the symptoms of mastocytosis are often similar to an allergic reaction. However, mastocytosis may occur spontaneously rather than be triggered by an allergen.

The FDA has cleared ImmunoCAP Tryptase, a new diagnostic assay, to measure the level of tryptase in the blood as an aid in the diagnosis of systematic mastocytosis. A persistently elevated baseline level of tryptase is an indication of possible mastocytosis.

"A physician cannot diagnose systematic mastocytosis based only on a physical examination. The FDA approval of the tryptase assay will provide doctors with an additional diagnostic tool," said Schwartz.

VCU first licensed the assay in 1993 to Pharmacia, now named Thermo Fisher Scientific Inc. The assay has one FDA-approved application helping to diagnose mastocytosis and several potential applications, including the diagnosis of systemic anaphylaxis, the prediction of increased risk for future episodes of severe anaphylaxis and use by medical examiners to evaluate cause of death.

"When somebody dies without a clear cause, by measuring postmortem tryptase levels, an increased level of tryptase provides support for an anaphylactic event near the time of death," said Schwartz.


'/>"/>
Contact: Frances Dumenci
fdumenci@vcu.edu
804-828-7701
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. FDA clears new IMMY and University of Nevada, Reno life-saving blood test
2. FDA clears biomarker test for ovarian cancer
3. Researchers find process that clears cholesterol and could reverse major cause of heart attack
4. Flightless mosquitoes developed to help control dengue fever
5. New tool developed to help guide pancreatic cyst treatment
6. Innovative Technology Developed at AGH Accurately Monitors Healthcare Professionals' Handwashing Practices, Study Shows
7. Innovative Motorized and Mobile Medical Procedure Table Developed By MTI, Inc.
8. New scanning technology developed in £7M research center
9. Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial
10. Human clinical trial of NIH-developed dengue vaccine begins
11. New diabetes risk assessment developed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/19/2020)... ATLANTA (PRWEB) , ... March 19, 2020 , ... ... training curriculum designed to teach Executive Function, shares a free Student Learning Exercise: ... to COVID-19, many parents and teachers are seeking resources to help with the ...
(Date:3/19/2020)... ... ... “We wanted to solve the challenges of safely getting testing for COVID-19 in ... reliable at home testing kit that can be processed quickly allows us to give ... their own home, while maintaining the health of the general public." , Members can ...
(Date:3/16/2020)... ... March 16, 2020 , ... To avoid ... Delta Human Services Authority is implementing several new universal health and safety measures ... clients and staff," said Dr. Monteic A. Sizer, executive director of Northeast Delta. ...
(Date:3/15/2020)... ... March 13, 2020 , ... ... are approximately 700,000 people with autism in the world, using a conservative rate ... have access to a life-changing intervention known as Applied Behavioral Analysis. ABA is ...
(Date:3/13/2020)... ... March 13, 2020 , ... The Berman Law Group today ... of China, Hubei Province, the City of Wuhan, and several Chinese government ministries, on ... The lawsuit was filed in the Southern District of Florida, and seeks billions of ...
Breaking Medicine News(10 mins):
(Date:3/20/2020)... BELTSVILLE, Md. (PRWEB) , ... March 20, 2020 , ... ... the previous 15 days to build a crowd-sourced database of detailed location information, such ... accurate view of a potential interaction or exposure to the virus. The app will ...
(Date:3/19/2020)... ... 19, 2020 , ... Combining multiple food allergies into a ... according to research scheduled for presentation at the 2020 American Academy of Allergy, ... situation with coronavirus disease 2019 (COVID-19). , A retrospective review was used ...
(Date:3/16/2020)... ... March 16, 2020 , ... ... patient education platform, with content available from numerous organizations. Docola enables healthcare ... they support patients before, after, or between face-to-face visits or on telemedicine ...
Breaking Medicine Technology: